Barrett oesophagus

Yonne Peters, Ali Al-Kaabi, Nicholas J. Shaheen, Amitabh Chak, Andrew Blum, Rhonda F. Souza, Massimiliano Di Pietro, Prasad G. Iyer, Oliver Pech, Rebecca C. Fitzgerald, Peter D. Siersema

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Barrett oesophagus (BE), the only known histological precursor of oesophageal adenocarcinoma (EAC), is a condition in which the squamous epithelium of the oesophagus is replaced by columnar epithelium as an adaptive response to gastro-oesophageal reflux. EAC has one of the fastest rising incidences of cancers in Western countries and has a dismal prognosis. BE is usually detected during endoscopic examination, and diagnosis is confirmed by the histological presence of intestinal metaplasia. Advances in genomics and transcriptomics have improved our understanding of the pathogenesis and malignant progression of intestinal metaplasia. As the majority of EAC cases are diagnosed in individuals without a known history of BE, screening for BE could potentially decrease disease-related mortality. Owing to the pre-malignant nature of BE, endoscopic surveillance of patients with BE is imperative for early detection and treatment of dysplasia to prevent further progression to invasive EAC. Developments in endoscopic therapy have resulted in a major shift in the treatment of patients with BE who have dysplasia or early EAC, from surgical resection to endoscopic resection and ablation. In addition to symptom control by optimization of lifestyle and pharmacological therapy with proton pump inhibitors, chemopreventive strategies based on NSAIDs and statins are currently being investigated for BE management.

Original languageEnglish (US)
Article number35
JournalNature Reviews Disease Primers
Issue number1
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Barrett oesophagus'. Together they form a unique fingerprint.

Cite this